WINDTREE THERAPEUTICS INC /DE/ WINT
Biological Products, (No Diagnostic Substances) · CIK 0000946486 · Fiscal year ends 1231
Revenue
$198.00K
Fiscal year ended 2019-12-31Operating income
-$24.89M
Fiscal year ended 2019-12-31Free cash flow
-$24.85M
Fiscal year ended 2019-12-31Valuation, from the filing
| Public float | $1.90M | Market value of stock held by non-affiliates, as stated on the cover page for 2024-06-28 |
|---|
| Float per share | $0.53 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-06-28, not today.
How this compares in its industry
Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
WINDTREE THERAPEUTICS INC /DE/ (WINT) reported revenue of $198.00K and net income of -$27.48M for the fiscal year ended 2019-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from WINDTREE THERAPEUTICS INC /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
Balance
Cash flow
Derived
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open WINT in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.